5 times Within The Past Five Days, Akero Therapeutics Inc. (AKRO) Hit A New High


Akero Therapeutics Inc. (NASDAQ:AKRO) finished Friday with an addition of $0.95 to close at $54.80, an upside of 1.76 percent. An average of 839,580 shares of common stock have been traded in the last five days. There was a gain of $6.91 in the past week, and it reached a new high 25 times over the past 12 months. The last 20 days have seen an average of 1,131,650 shares traded, while the 50-day average volume stands at 785,730.

AKRO stock has increased by 17.85% in the last month. The company shares reached their 1-month lowest point of $35.80 on 12/19/22. With the stock rallying to its 52-week high on 12/30/22, shares of the company touched a low of $7.52 and a high of $53.98 in 52 weeks. It has reached a new high 25 times so far this year and achieved 159.10% or $33.65 in price. In spite of this, the price is up 1.52% from the 52-week high.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…


Insider Transactions

AKRO stock investors should be aware that Akero Therapeutics Inc. (AKRO) stock had its last reported insider trading activity 2 days ago on Dec 29. In this transaction, the insider spent $1,037,119. Chief Scientific Officer, Rolph Timothy, disposed of 1,700 shares at a price of $50.00 on Dec 28. The insider now owns more than $85,006 worth of shares. Prior to that, Chief Financial Officer White William Richard went on to Sale 999 shares at $49.76 each on Dec 28. An amount of $49,714 was transacted.

Valuation Metrics

Akero Therapeutics Inc. (AKRO) stock’s beta is -0.83. Other valuation ratios to consider include the price-to-book (PB) ratio at 6.17.

Financial Health

The quick ratio of Akero Therapeutics Inc. for the three months ended June 29 was 15.00, and the current ratio was 15.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.03 and a total debt to equity ratio of 0.03 for the quarter ending June 29.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Akero Therapeutics Inc.’s return on assets was -52.20%.

Earnings Surprise

For the three-month period that ended June 29, Akero Therapeutics Inc. had $9.45 million in total debt. The company posted a net income of -$35.54 million in the quarter, while revenues of -$27.4 million were grew 31.54%. The analyst consensus anticipated Akero Therapeutics Inc.’s latest quarter earnings to come in at -$0.86 per share, but it turned out to be -$0.77, a 10.50% surprise. Shareholders own equity worth $46.76 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Akero Therapeutics Inc. (AKRO) price momentum. RSI 9-day as of the close on 30 December was 74.37%, suggesting the stock is Overbought, with historical volatility in this time frame at 125.25%.

As of today, AKRO’s price is $51.37 +14.43% or $6.91 from its 5-day moving average. AKRO is currently trading +19.94% higher than its 20-day SMA and +325.47% higher than its 100-day SMA. However, the stock’s current price level is +34.84% above the SMA50 and +292.55% above the SMA200.

The stochastic %K and %D were 98.77% and 98.60%, respectively, and the average true range (ATR) was 3.17. With the 14-day stochastic at 99.84% and the average true range at 3.05, the RSI (14) stands at 69.76%. The stock has reached 4.92 on the 9-day MACD Oscillator while the 14-day reading was at 6.08.

Analyst Ratings

Evercore ISI upgraded Akero Therapeutics Inc. (NASDAQ: AKRO) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as an In-line. The consensus rating for Akero Therapeutics Inc. (AKRO) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AKRO, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.

What is AKRO’s price target for the next 12 months?

Analysts predict a range of price targets between $40.00 and $64.00, with a median target of $50.00. Taking a look at these predictions, the average price target given by analysts for Akero Therapeutics Inc. (AKRO) stock is $52.00.


Please enter your comment!
Please enter your name here